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Abstract
Background: Two clinical scoring systems, the status epilepticus severity score (STESS) and the epidemiology-based
mortality score in status epilepticus (EMSE), are used to predict mortality in patients with status epilepticus (SE).
The aim of this study was to compare the outcome-prediction function of the two scoring systems regarding
in-hospital mortality using a multicenter large cohort of adult patients with SE. Moreover, we studied the potential
role of these two scoring systems in predicting the functional outcome in patients with SE.
Methods: The SE cohort consisted of patients from the epilepsy centers of eight academic tertiary medical centers
in South Korea. The clinical and electroencephalography data for all adult patients with SE from January 2013 to
December 2014 were derived from a prospective SE database. The primary outcome variable was defined as
in-hospital death. The secondary outcome variable was defined as a poor functional outcome, i.e., a score of 1–3
on the Glasgow Outcome Scale, at discharge.
Results: Among the 120 non-hypoxic patients with SE recruited into the study, 16 (13.3 %) died in the hospital and
64 (53.3 %) were discharged with a poor functional outcome. The receiver-operating characteristic (ROC) curve for
prediction of in-hospital death based on the STESS had an area under the curve of 0.673 with an optimal cutoff
value for discrimination (best match for both sensitivity (0.56) and specificity (0.70)) that was ≥4 points. The two
combinations of elements of the EMSE system (EMSE-ALDEg and EMSE-ECLEg) predicted not only in-hospital
mortality with the best match for sensitivity (more than 0.6) and specificity (more than 0.6), but also a poor
functional outcome with the best match for both sensitivity (>0.7) and specificity (>0.6). STESS did not predict a
poor functional outcome (area under the ROC, 0.581; P = 0.23).
Conclusion: Although the EMSE is a clinical scoring system that focuses on individual mortality, we did not find
differences between the EMSE and STESS in the prediction of in-hospital death. The EMSE was useful in predicting
poor functional outcome, as it was significantly better than STESS.
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Background
Status epilepticus (SE) is a common neurological emer-
gency that is associated with high rates of mortality and
morbidity. Thus, rapid initiation of treatment tailored to
the severity of SE is required. In this regard, prediction
of bad outcome is needed to avoid underdetection and
undertreatment of SE. Adequate prediction of good
outcome is crucial to minimize risks of potentially
harmful overtreatment. Two clinical scoring systems,
the status epilepticus severity score (STESS) [1] and the
epidemiology-based mortality score in status epilepticus
(EMSE) [2], are available to predict the risk of death at SE
onset.
The STESS consists of four clinical parameters, in-
cluding level of consciousness, worst seizure type, age,
and history of previous seizure [1]. Validation studies
have reported that a score of ≥3 points on the STESS
indicates a poor outcome [1, 3]; in contrast, a recent
study reported a different optimized cutoff value for sur-
vival versus death (≥4 points) [4]. The EMSE is another
clinical scoring system that is used for outcome predic-
tion in patients with SE [2]. It was published with both
three (etiology, age, comorbidity; EAC) and four (eti-
ology, age, comorbidity, electroencephalography (EEG);
EACE) parameters, and scores “mortality risk points”. It
has been reported that the combination of EMSE-EAC
and EMSE-EACE is superior to STESS in explaining in-
dividual mortality in SE; however, no external validation
study of this issue has been performed.
Disability among survivors and return to the patients’
premorbid state may also be very interesting and im-
portant outcome parameters. However, the two clinical
scoring systems were not initially tested for prediction
of individual functional outcome [1, 2]. The aim of this
study was to compare the outcome-prediction functions
of the STESS and EMSE regarding in-hospital mortality in
a large prospective cohort of adult patients with SE. Add-
itionally, we studied the potential role of these two scoring




This study was performed in the epilepsy centers of
eight academic tertiary hospitals in South Korea. The
clinical and EEG data of all adult patients with SE from
January 2013 to December 2014 were derived from a
prospective SE database. The study was approved by the
institutional review boards of the lead study center
(Korea University Anam Hospital, Seoul, South Korea;
IRB no. ED-13157) and all other participating hospitals
(see Additional file 1) in accordance with the standards
of the Declaration of Helsinki. Informed consent was
waived.
Definition of SE
SE was defined as the presence of clinical and EEG evi-
dence of seizures lasting at least 5 min or of repeated
seizures without intervening recovery of consciousness
[5]. The types of SE were classified according to the initial
manifestation as: (1) generalized convulsive SE (GCSE)
and (2) non-convulsive SE (NCSE). If SE began with a
generalized tonic–clonic seizure with continuous con-
vulsion or evolution to a non-convulsive status, it was
defined as GCSE. NSCE was defined as a condition with
prolonged electrographic seizure activity resulting in non-
convulsive behavioral and/or cognitive changes from the
baseline [6]. Refractory SE was defined as SE that was un-
responsive to one adequate dose of benzodiazepine and
one antiepileptic drug.
Data collection and scoring of SE
Information was collected regarding the clinical and EEG
features at SE onset. The data included all integral com-
ponents of the STESS and EMSE, i.e., age, etiology of SE
(categorized as proposed by the International League
Against Epilepsy (ILAE)) [7], history of epilepsy, worst
seizure type, level of consciousness (LOC) before treat-
ment, seizure duration, initial EEG pattern, and comorbid-
ity, and were determined at SE onset. The STESS was
calculated as reported previously (Fig. 1a) [1]. Moreover,
the mortality risk points of six EMSE parameters in the
fields of etiology, age, LOC, seizure duration, EEG pattern,
and comorbidity were collected, and the sum score of all
possible combinations of EMSE elements was calculated
as reported previously (Fig. 1b) [2].
Outcome
The primary outcome variable was defined as death in
the hospital, which also included patients who were
transferred to a palliative care unit when death was ex-
pected in the near future. The secondary outcome vari-
able was defined as a poor functional outcome, i.e., a
score of 1–3 on the Glasgow Outcome Scale (GOS), at
discharge.
Statistics
Statistical analyses were performed using the SPSS
20.0KO software for Windows. Categorized variables
were summarized as counts and proportions, and con-
tinuous variables were summarized as median value and
range. The categorical variables were compared using
Fisher’s exact test or the chi-squared test, and continu-
ous categorical variables were compared using Student’s
t-test or the Mann–Whitney U test. P values ≤0.05 were
considered statistically significant.
We defined discrimination as the ability of the STESS
and EMSE to segregate survivors from non-survivors
and to differentiate patients who had a good functional
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outcome from patients who had a poor functional out-
come. This was quantified by calculating the c static analo-
gous to the area under a receiver-operating characteristic
curve (AUROC) [8], which estimated the probability that a
model assigned a higher risk of in-hospital mortality or a
poor functional outcome to those who had a high score on
each scoring system compared with those with a low score
on each system. Youden’s index was calculated to identify
the optimal cutoff point of each score regarding sensitivity
and specificity for the prediction of outcomes. Sensitivity,
specificity, positive and negative predictive value (PPV and
NPV, respectively), and accuracy were calculated for the
EMSE and STESS.
To determine the optimal combination of EMSE ele-
ments we used a two-step approach. First, we chose
EMSE combinations for in-hospital death that (1) had a
higher AUROC than the AUROC of the STESS, (2) had
a high sensitivity (>0.6) and specificity (>0.6) at the
calculated cutoff point, and (3) combined less than four
parameters. Next, we analyzed the predicting power of
choosing an EMSE combination for functional outcome,
AUROC, and calculated cutoff point. The EMSE com-
bination that could simultaneously predict in-hospital
mortality and functional outcome and had high sensi-
tivity and specificity was considered the optimal EMSE
combination.
Fig. 1 Evaluation example for a STESS and b EMSE systems. ASID after status ictal discharge, CNS central nervous system, EEG electroencephalography,
EMSE epidemiology-based mortality score in status epilepticus, GPD generalized periodic discharge, LOC level of consciousness, LPD lateralized periodic
discharge, STESS status epilepticus severity score
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Results
Demographics
One hundred twenty non-hypoxic patients with SE from
eight centers (3–24 patients from each center) were
enrolled in this study. The demographics and clinical
characteristics of the cohort are summarized in Table 1.
Among the 120 patients, 16 (13.3 %) died in the hospital
and 64 (53.3 %) were discharged with a poor functional
outcome. Refractory SE (22.1 % of survivors versus 56.2 %
of non-survivors; P = 0.007), a stuporous or comatose
mental status at pretreatment (48.1 % of survivors versus
87.5 % of non-survivors; P = 0.003), and the presence of
periodic discharge at the initial EEG (50.0 % of survivors
versus 81.2 % of non-survivors; P = 0.029) were associated
with in-hospital mortality. Older age (a median of 54 years
for a good functional outcome versus 67 years for a poor
functional outcome; P = 0.036), refractory SE (15.1 % for a
good versus 35.8 % for a poor functional outcome; P =
0.011), seizure duration over 1 hour (64.2 % for a good
versus 80.6 % for a poor functional outcome; P = 0.043),
the presence of burst suppression (9.4 % for a good versus
26.9 % for a poor functional outcome; P = 0.016), and the
presence of periodic discharge at the initial EEG (32.1 %
for a good versus 71.6 % for a poor functional outcome;
P < 0.0001) were associated with a poor functional out-
come at discharge.
Performance of the STESS and EMSE in predicting
in-hospital death
The receiver-operating characteristic (ROC) curve for
predicting in-hospital death based on the STESS had an
area under the curve (AUC) of 0.673 with an optimal
cutoff value for discrimination (best match for both sen-
sitivity (0.56) and specificity (0.70)) that was ≥4 points.
Twenty-eight combinations of the EMSE (3 combi-
nations with 2 domains, 12 with 3 domains, 8 with 4
domains, and all combinations with 5 or 6 domains) had
an AUROC >0.700 (Additional file 2: Table S1). Among
the eight EMSE combinations that had the highest
AUROC, EMSE-ALDEg (age-loss of consciousness-
duration-EEG) and EMSE-ECLEg (etiology-comorbidity-
loss of consciousness-EEG) were the combinations that
exhibited the best match for sensitivity (>0.6) and speci-
ficity (>0.6) above their calculated cutoff values (Table 2).
There was no statistically significant difference between
the ROC for predicting in-hospital death based on the
EMSE-ALDEg and EMSE-ECLEg, and the ROC for pre-
dicting in-hospital death based on the STESS (Fig. 2).
There were no significant differences between the test
performance of EMSE-EAC and EMSE-EACE with ini-
tial published cutoff, EAC-27 and EACE-64 and those of
STESS-3 and STESS-4 (Fig. 3). The lowest total score of
EMSE in non-survivors was 22 points for EMSE-EAC
and 44 points for EMSE-EACE.
Prediction of functional outcome at discharge based on
the EMSE and STESS
All eight EMSE combinations that had the highest score
for predicting in-hospital mortality had an AUC >0.740
for predicting the functional outcome (Table 3). Six of
Table 1 Demographic and clinical characteristics of the patients
Total (n = 120)
Gender (female, %) 56 (46.7 %)
Age (years, median (range)) 63.5 (20–91)
Age (>65 years) 57 (47.5 %)
Etiology of SE
Acute symptomatic 50 (41.7 %)
Remote symptomatic 44 (36.7 %)
Progressive symptomatic 9 (7.5 %)
Idiopathic/cryptogenic 17 (14.2 %)
SE dynamics
Generalized convulsive SE only 39 (32.5 %)
Non-convulsive SE 50 (41.7 %)
Generalized convulsive SE evolving
into non-convulsive SE
19 (15.8 %)
Absence SE 1 (0.8 %)
First episode of SE 106 (88 %)
Refractory SE 28 (23.3 %)
LOC pretreatment
Awake or somnolent/confused 56 (46.7 %)
Stuporous or comatose 64 (53.3 %)
Worst seizure type
Simple partial, CPS, absence, myoclonic 48 (40.0 %)
Generalized convulsive 48 (40.0 %)
Non-convulsive SE in coma 24 (20.0 %)
History of previous epilepsy 77 (64.2 %)
Duration of pretreatment (>1 hour) 88 (73.3 %)
Duration of seizure
>5 min, <30 min 10 (8.3 %)
3 min or longer, but <1 hour 15 (12.5 %)
1 hour or longer 95 (79.2 %)
Charlon’s Comorbidity index total
0 33 (27.5 %)
1–2 41 (34.1 %)
3 or more 46 (38.4 %)
EEG–BS 23 (19.2 %)
PDs 65 (54.2 %)
Treated on NICU 57 (47.5 %)
Days on NICU (median (range)) 8 (1–125)
Values are given as n (%) unless otherwise indicated. BS burst suppression, CPS
complex partial seizure, EEG electroencephalography, LOC level of consciousness,
NICU neurological intensive care unit, PD periodic discharge, SE status epilepticus
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the eight EMSE combinations had the same or a higher
calculated cutoff value for predicting the functional out-
come compared with those for predicting in-hospital
mortality. The ROC for predicting the functional out-
come based on the EMSE-ALDEg and ECLEg had an
AUC of 0.747 and 0.793, respectively, with an optimal
cutoff value for discrimination (best match for both sen-
sitivity (0.73 and 0.72, respectively) and specificity (0.74
and 0.75, respectively)) that was >58 and 77 points, re-
spectively. The ROC for predicting the functional out-
come based on the STESS had an AUC of 0.610, which
was statistically inferior to that obtained based on the
EMSE (Fig. 4).
Discussion
This was the first independent, external, head-to-head
validation study of the predictive accuracy of two clinical
scoring systems (STESS and EMSE) that are used for pre-
dicting in-hospital mortality among patients with SE. We
also studied the potential role of these two scoring systems
in predicting the functional outcome in these patients.
Prediction of in-hospital mortality
We found that an EMSE-ALDEg (>60, age–loss of
consciousness–duration–EEG) or an EMSE-ECLEg (>81,
etiology–comorbidity–loss of consciousness–EEG) was
the best combination for predicting in-hospital mortality.
At these cutoff points for the EMSE-ALDEg and EMSE-
ECLEg, the NPV was 44.5 % and 95.6 % and the PPV
was 100 % and 25.5 %, respectively. A previous study
reported that a different combination of EMSE parame-
ters, EAC (etiology–age–comorbidity) and EACE (eti-
ology–age–comorbidity–EEG), was the best combination
to explain individual mortality, with 100 % NPV and
68.8 % PPV [2]. Demographic and methodological differ-
ences may explain why the best EMSE combination was
different and the PPV was lower compared with the previ-
ous study. The in-hospital mortality and the proportion of
patients over age 65 were higher in the previous report [2]
than they were in our study (23.9 % versus 13.3 % and
62.0 % versus 47.5 %, respectively). Our population had
64.2 % patients with pre-existing epilepsy compared to
50 % in the initial EMSE population. This impacts results
as the ceiling effect of STESS vanishes with increasing per-
centage of pre-existing epilepsy and helps to explain the
lack of significant differences in mortality prediction. Only
27.5 % of patients had no comorbidity in our study com-
pared to 43.5 % in the initial EMSE population. The
methods used to decide on the optimized cutoff value for
the EMSE combination in our study were also different
from those used in the previous one. The lowest total
score on the EMSE combination in non-survivors was
taken as the cutoff value to improve the PPV in the previ-
ous study, whereas the calculated cutoff value of the ROC
Table 2 Quantitative description of the choice of EMSE
combinations and STESS for predicting death
AUROC
(cutoff point)
Sensitivity Specificity NPV PPV Accuracy
EMSE-EAC 0.633 (>37) 0.17 0.92 0.47 0.75 0.51
EMSE-ECEg 0.750 (>71) 0.81 0.56 0.95 0.22 0.59
EMSE-ELEg 0.764 (>47) 1.00 0.46 1.00 0.22 0.53
EMSE-LDEg 0.744 (>47) 0.21 1.00 0.40 1.00 0.48
EMSE-EACEg 0.712 (>62) 0.94 0.44 0.98 0.21 0.51
EMSE-EALEg 0.771 (>54) 1.00 0.47 1.00 0.22 0.54
EMSE-ECLEg 0.745 (>81) 0.81 0.63 0.96 0.25 0.66
EMSE-ELDEg 0.766 (>75) 0.23 1.00 0.47 1.00 0.59
EMSE-ALDEg 0.745 (>60) 0.22 1.00 0.44 1.00 0.52
STESS 0.673 (≥4) 0.56 0.70 0.91 0.22 0.68
AUROC area under a receiver-operating characteristic curve, EMSE epidemiology-
based mortality score in status epilepticus (E, etiology; A, age; C, comorbidity; L,
level of consciousness at pretreatment; D, duration; Eg, electroencephalography),
NPV negative predictive value, PPV positive predictive value, STESS status
epilepticus severity score
Fig. 2 Receiver-operating characteristic curves for EMSE-ALDEg,
ECLEg and STESS for predicting in-hospital mortality. Comparison
P value: a = 0.9928, b = 0.3205, c = 0.4591. AUROC area under a
receiver-operating characteristic curve, CI confidence interval, EMSE
epidemiology-based mortality score in status epilepticus (E,
etiology; A, age; C, comorbidity; L, level of consciousness at
pretreatment; D, duration; Eg, electroencephalography), STESS status
epilepticus severity score
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was used in our study. Thus high EMSE score in our
population could be the main reason for low-to-moderate
performance of EMSE in predicting mortality. Ninety
five patients (79.2 %) scored 33 points for seizure dur-
ation and 22 (19.2 %) and 65 (54.2 %) scored 60 and 50
points for EEG, respectively. Forty six patients (38.4 %)
had 3 or more Charlson’s comorbidity index.
Here, the optimized cutoff value of the STESS was ≥4
(best match for both sensitivity (0.69) and specificity (0.41)),
which was different from that proposed by the initial study
(≥3 points) [3]. A recent independent external validation
study of the STESS reported that a cutoff value of ≥4 points
was optimal for predicting in-hospital death [4]. At this
cutoff point, the NPV was 91.28 % and the PPV was
22.50 %. These results are very similar to those of prior
studies of the STESS [3, 4]. There was no statistically
significant difference between the predictive power of the
STESS and the EMSE regarding in-hospital mortality.
Fig. 3 Comparison of test performances between epidemiology-based mortality score in status epilepticus (EMSE) etiology–age–comorbidity
(EAC)-27, etiology–age–comorbidity–EEG (EACE)-65, status epilepticus severity score (STESS)-3 and STESS-4. Negative predictive value (NPV):
P = 0.0323 for EAC versus EACE, P = 0.0141 for EAC versus STESS-3, P = 0.8672 for EAC versus STESS-4, P = 0.1633 for EACE versus STESS-3, P = 0.2221 for
EACE versus STESS-4, P = 0.342 for STESS-3 versus STESS-4; positive predictive value (PPV): P = 0.0192 for EAC versus EACE, P = 0.1185 for EAC versus
STESS-3, P = 0.2268 for EAC versus STESS-4, P = 0.0063 for EACE versus STESS-3, P = 0.0215 for EACE versus STESS-4, P = 0.424 for STESS-3 versus STESS-4;
accuracy: P = 0.3017 for EAC versus EACE, P = 0.0927 for EAC versus STESS-3, P = 0.5753 for EAC versus STESS-4, P = 0.7069 for EACE versus STESS-3,
P = 0.0635 for EACE versus STESS-4, P = 0.2174 for STESS-3 versus STESS-4; level of significance corrected for multiple testing P≤ 0.0044
Table 3 Quantitative description of the choice of EMSE
combinations and STESS for predicting functional outcomes
AUROC
(cutoff point)
Sensitivity Specificity NPV PPV Accuracy
EMSE-ECEg 0.777 (>51) 0.82 0.60 0.73 0.72 0.73
EMSE-ECLEg 0.793 (>77) 0.72 0.75 0.68 0.79 0.73
EMSE-ALDEg 0.747 (>58) 0.73 0.74 0.60 0.84 0.73
STESS 0.610 (≥4) 0.81 0.44 0.54 0.75 0.61
AUROC area under a receiver-operating characteristic curve, EMSE
epidemiology-based mortality score in status epilepticus (E, etiology; A, age;
C, comorbidity; L, level of consciousness at pretreatment; D, duration; Eg,
electroencephalography), NPV negative predictive value, PPV positive
predictive value, STESS status epilepticus severity score
Fig. 4 Receiver-operating characteristic curves for EMSE-ALDEg,
EMSE-ECLEg and STESS for predicting poor functional outcome at
discharge. Comparison P value: a = 0.1427, b = 0.0180, c = 0.0014.
AUROC area under a receiver-operating characteristic curve,
CI confidence interval, EMSE epidemiology-based mortality score in
status epilepticus (E, etiology; A, age; C, comorbidity; L, level of
consciousness at pretreatment; D, duration; Eg, electroencephalography),
STESS status epilepticus severity score
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Prediction of functional outcome
In this study, an EMSE-ALDEg (>58) or an EMSE-
ECLEg (>77) was the best combination for simultan-
eously predicting functional outcome at discharge and
in-hospital death. In relation to prediction of the func-
tional outcome, the EMSE-ALDEg and EMSE-ECLEg
had an NPV of 60.4 % and 67.8 % and a PPV of 84.3 %
and 78.7 %, respectively. This means that a positive test
had a ~75 % chance of reflecting a bad outcome and a
negative test had a ~70 % chance of reflecting a good out-
come. Therefore, the EMSE-ALDEg and EMSE-ECLEg
may be useful for simultaneously predicting survival and
the functional outcome at discharge in patients with SE.
In contrast, the STESS was significantly less useful in pre-
dicting the functional outcome.
In our study, less than half of the patients (56 out of
120, 47.7 %) were discharged with a good functional
outcome. Although long-term outcome data were not
collected in our study, the neurological function could
be recovered after discharge. In a recent review of re-
fractory or super-refractory SE, the long-term outcome
was death (35 %), severe neurological deficit (13 %), mild
neurological deficit (13 %), undefined deficit (4 %), and
recovery to the baseline (35 %) among a total of 596
cases [9]. A prospective observational cohort study re-
ported that 146 out of 248 patients (58.9 %) with convul-
sive SE achieved a good recovery (51 with GOS 4 and 95
with GOC 5) at 90 days after discharge from an inten-
sive care unit [10]. Older age, refractory SE, a longer
duration of seizure before treatment (over 1 hour), and
the presence of burst suppression or periodic discharge
at EEG were associated with a poor functional outcome
at discharge in our study. A longer seizure duration, the
presence of cerebral insult, and refractory convulsive
SE were associated with a poor long-term functional
outcome [10].
Maximum performance of the EMSE was achieved by
incorporating EEG patterns categorized as lateralized or
generalized periodic discharges. The presence of general-
ized periodic EEG discharges was a prognostic factor,
with an odds ratio of 8.5 (95 % confidence interval 1.7–
43.4; P = 0.01) for a poor outcome in a multivariate
model [11]. Nei et al. reported that periodic discharges,
either lateralized or generalized, are associated with a
poor outcome in SE [12]. Refractory SE was defined as
SE that was unresponsive to treatment with at least two
or more antiepileptic drugs and is a well-known inde-
pendent factor for outcome prediction [5]. Because
patients with SE usually undergo their first EEG study
after first- or second-line antiepileptic drug treatment in
clinical practice, the EEG abnormalities observed in this
study may in fact reflect a refractory SE. Ideally, the best
scoring system in clinical practice should be available
at the most relevant time such as entering hospital or
diagnosing the SE. However, in many hospital dealing
with SE, the EEG has been recorded hours to days
later. It could be limited to apply the EMSE system
in clinical practice.
Strengths and limitations
The strengths of this study were the inclusion of a large
multicenter prospective cohort and the fact that its in-
vestigators were independent from the research group
that developed the two clinical scoring systems. Data
collection regarding the integral variables of the EMSE
and STESS was performed blindly to other clinical data
to avoid investigator biases. The limitations of this study
were the retrospective nature of the analysis from the
dataset, because our cohort was not designed for this
analysis. The Charlson’s comorbidity index and seizure
duration were scored retrospectively. Our database could
not represent the epidemiology of South Korea and it is
hard to directly compare our result with original research
on EMSE score because only 120 cases of SE were
enrolled from eight hospitals (3–24 patients from each
center) for 2 years in an area with an estimated 26 million
inhabitants.
Conclusion
This is the first independent, external, head-to-head
validation study of the predictive accuracy of STESS and
EMSE score using a multicenter prospective cohort. Our
results suggest that there was no statistically significant
difference between the predictive power of two scoring
systems regarding in-hospital mortality. It is possible
to predict functional outcome (EMSE-ADLEg-58 or
EMSE-ECLEg-77) and in-hospital death (EMSE-ADLEg-
60 or EMSE-ECLEg-81) using the EMSE score, simultan-
eously. However, the best combination of EMSE remained
unclear. The optimized cutoff value of STESS could be at
greater than or equal to 4 points to predict in-hospital
death.
Key messages
 This is the first independent, external, validation
study of the predictive accuracy of STESS and
EMSE score using a multicenter prospective cohort.
 There was no statistically significant difference
between the predictive power of two scoring system
regarding in-hospital mortality.
 It is possible to predict functional outcome and
in-hospital death using the EMSE score, simultaneously.
 The STESS was significantly less useful in
predicting the functional outcome.
 The optimized cutoff value of STESS could be
at greater than or equal to 4 points to predict
in-hospital death.
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